SCHEMBL3418984

SCHEMBL3418984

NC(=O)C1(C(=O)N(c2ccccc2)c2ccc(Oc3ccnc4cc(OCCCN5CC(O)C6(CC6)C5)ccc34)c(F)c2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 3/20 0.42
MET P08581 18/20 0.41
PLK4 O00444 1/20 0.36
STK25 O00506 1/20 0.36
CIT O14578 1/20 0.36
AURKA O14965 1/20 0.36
CHUK O15111 1/20 0.36
MUSK O15146 1/20 0.36
EPHB6 O15197 1/20 0.36
MAPK13 O15264 1/20 0.36
MAP3K13 O43283 1/20 0.36
DAPK3 O43293 1/20 0.36
MAP3K7 O43318 1/20 0.36
RIPK2 O43353 1/20 0.36
JAK2 O60674 1/20 0.36
ROCK2 O75116 1/20 0.36
PAK3 O75914 1/20 0.36
CDKL5 O76039 1/20 0.36
STK10 O94804 1/20 0.36
PRKD3 O94806 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL373947 0.95 MET (0.42) AXLMETPLK4STK25CIT
SCHEMBL3421924 0.89 MET (0.54) AXLMETPLK4STK25CIT
SCHEMBL3421729 0.87 MET (0.36) AXLMETEGFRIGF1RKDR
SCHEMBL374071 0.85 MET (0.55) AXLMETPLK4STK25CIT
SCHEMBL2158304 0.84 AXL (0.39) AXLMETIGF1RKDRMERTK
SCHEMBL461519 0.83 AXL (0.38) AXLMETIGF1RKDRMERTK
Hydrochloric Acid SCHEMBL377110 0.83 MET (0.39) AXLMETPLK4STK25CIT
SCHEMBL2151233 0.82 PLAU (0.39) AXLMETIGF1RKDRMERTK
SCHEMBL13400730 0.82 MET (0.54) AXLMETPLK4STK25CIT
SCHEMBL13433203 0.81 AXL (0.49) AXLMETPLK4STK25CIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2532657-B9 Compounds and methods of use SUNSHINE LAKE PHARMA CO LTD (CN) 2017-04-19 EP disclosed
EP-2532657-B1 Compounds and methods of use SUNSHINE LAKE PHARMA CO LTD (CN) 2016-08-31 EP disclosed
US-8426585-B2 Compounds comprising a spiro-ring Xi, Ning (US) 2013-04-23 US disclosed
US-20120315247-A1 COMPOUNDS COMPRISING A SPIRO-RING AND METHODS OF USE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2012-12-13 US disclosed
US-8293897-B2 Compounds comprising a spiro-ring and methods of use Xi, Ning (US) 2012-10-23 US disclosed
US-20100093727-A1 COMPOUNDS AND METHODS OF USE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2010-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093727-A1 COMPOUNDS AND METHODS OF USE PRKDC, PRKACA, PRKX AXL 719/4885MET 302/4885PLK4 573/4885
US-20120315247-A1 COMPOUNDS COMPRISING A SPIRO-RING AND METHODS OF USE CDC42BPG, HRAS, PTPRJ AXL 1146/4885MET 732/4885PLK4 286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.